Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461–2469, doi: 10.1093/eurheartj/ehp363]

Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive... The Editor’s Page 1023 11. Fanelli D. How many scientists fabricate and falsify research? A systematic review surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249: and meta-analysis of survey data. PLoS One 2009;4:e5738. 921–926. 12. Nallamothu B, Lu¨scher TF. Moving from impact to influence: measurement and 30. Poldermans D, Schouten O, Benner R, van Urk H, Verhagen HJ, Khan N, the changing role of medical journals. Eur Heart J 2012;33:2892–2996. Feringa H, Dunkelgrun M, Bax JJ, Boersma E. Fluvastatin XL use is associatedwith 13. Marcus A, Oransky I. A retraction epidemic. New York Times 2012;April, p7. improved cardiac outcome after major vascular surgery. Results from a rando- 14. Steen RG. Retractions in the scientific literature: is the incidence of research fraud mized placebo controlled trial: DECREASE III. Circulation 2008;118:S792. increasing? J Med Ethics 2011;37:249–253. 31. Poldermans D, Bax JJ, Schouten O, Neskovic AN, Paelinck B, Rocci G, van 15. Fang FC, Casadevall A. Retracted science and the retraction index. Infect Immun Dortmont L, Durazzo AE, van de Ven LL, van Sambeek MR, Kertai MD, 2011;79:3855–3859. Boersma E. Should major vascular surgery be delayed because of preoperative 16. Notice of Concern. J Am Coll Cardiol 2012;60:2696–2697. cardiac testing in intermediate-risk patients receiving beta-blocker therapy with 17. Wise J. Extent of Durch psychologist’s trial fraud was unprecendented. BMJ 2011; tight heart rate control? J Am Coll Cardiol 2006;48:964–969. 343:969. 32. Poldermans D, Bax JJ. Dobutamine echocardiography: a diagnostic tool comes of 18. O’Riordan M. Erasmus MC fires Poldermans; ESC reviews his work. www. age. Eur Heart J 2003;24;1541–1542. theheart.org/article/1315171.do (27 February 2013). 33. Hoeks SE, Bax JJ, Poldermans D. Should the ACC/AHA guidelines be changed in 19. Expression of concern. Circ Res 2012;110:e47. patients undergoing vascular surgery? Eur Heart J 2005;26:2358–2360. 20. Yoshiki Y. Concerns about the Jikei Heart Study. Lancet 2012;379:e48. 34. Poldermans D, Bax . Selecting optimal non-invasive cardiac imaging stress test in 21. Shimokawa H. Urgent announcement from the editor-in-chief concerning atricle intermediate-risk patients using cost effectiveness analysis. Eur Heart J 2006;27: retraction. Circ J 2013;77:552b. 2378–2379. 22. Lu¨scher TF. In search of the right word: a statement of the HEART Group on 35. Hoeks SE, Bax JJ, Poldermans D. Indications of prophylactic coronary revascular- scientific language. Eur Heart J 2013;34:7–9. ization in patients undergoing major vascular surgery; the saga continues. Eur 23. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. Heart J 2007;28:519–521. p104–108. 36. Schouten O, Bax JJ, Poldermans D. Preoperative cardiac risk assessment in vascu- 24. Stewart WW, Feder N. The integrity of the scientific literature. Nature 1987;325: lar surgery patients; seeing beyond the perioperative period. Eur Heart J 2008;29: 207–214. 283–284. 25. Braunwald E. On analysing scientific fraud. Nature 1987;325:215–216. 37. Flu WJ, Van Kuijk JP, Gorscan J, Poldermans D. Three-dimensional speckle track- 26. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. ing echocardiography: a novel approach in the assessment of left ventricular p110–112. volume and function? Eur Heart J 2009;30:2304–2307. 27. Broad WJ. Imbroglio at Yale: emergence of a fraud. Science 1980;210:38–41 and 38. Van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chronchol M, Vidakowic R, 10:171–173. Verhagen HJ, Bax JJ, Poldermans D. Long-term prognosis of patients with periph- 28. Feringa HH, Elhendy A, Bax JJ, Boersma E, de Jonge R, Schouten O, eral arterial disease with or without polyvascular atherosclerotic disease. Eur Karagiannis SE, Schinkel AF, Lindemans J, Poldermans D. Baseline plasma Heart J 2010;31:992–999. N-terminal pro-B-type natriuretic peptide is associated with the extent of 39. Wednesday 28 November 2012. stress-induced myocardial ischemia during dobutamine stress echocardiography. 40. Lu¨scher TF, Gersh B, Brugada J, Landmesser U, Ruschitzka F, Serruys PW on Coron Artery Dis 2006:17; 255–259 and Feringa HH, Bax JJ, Elhendy A, de Jonge behalf of the new editorial board. The European Heart Journal goes global: the R, Lindemans J, Schouten O, van den Meiracker AH, Boersma E, Schinkel AF, road ahead of the editorial team 2009–2011. Eur Heart J 2009;30:1–5. Kertai MD, van Sambeek MR, Poldermans D. Association of plasma N-terminal 41. Head SJ, Kaul S, Bogers AJJC, Kappetein AP. Non-inferiority study design: lessons pro-B-type natriuretic peptide with postoperative cardiac events in patients to be learned from cardiovascular trials. Eur Heart J 2012;33;1318–1324. undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol 42. Heinze G, Ju¨ni P. An overview of the objectives of the approaches to propensity 2006;98:111–115. analysis. Eur Heart J 2011;32;1704–1708. 29. Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van 43. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Poorten F, Bax JJ, Thomson IR, Poldermans D; Dutch Echocardiographic Trikalinos TA, Kitsios GD. Do observational studies using propensity score Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisopro- methods agree with randomized trials? A systematic comparison of studies on lol and fluvastatin for the reduction of perioperative cardiac mortality and myo- acute coronary syndromes. Eur Heart J 2012;33:1893–1901. cardial infarction in intermediate-risk patients undergoing noncardiovascular 44. Norman C. Reduce fraud in seven easy steps. Science 1984;224;581. doi:10.1093/eurheartj/eht030 Retraction Online publish-ahead-of-print 1 February 2013 ............................................................................................................................................................................. Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461–2469, doi: 10.1093/eurheartj/ehp363]. 1 1 2 1 1 Takahisa Sawada , Hiroyuki Yamada , Bjo¨rn Dahlo¨f , and Hiroaki Matsubara for the KYOTO HEART Study Group 1 2 Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kajiicho 465, Kamigyoku, Kyoto 602-8566, Japan and Department of Medicine, Sahlgrenska University Hospital/Ostra, Go¨teborg, Sweden This article has been retracted by the journal. Critical problems existed with some of the data reported in the above paper. The editors of the European Heart Journal hereby retract this paper and discourage citations of it. Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013. For permissions please email: journals.permissions@oup.com http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Heart Journal Oxford University Press

Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461–2469, doi: 10.1093/eurheartj/ehp363]

Loading next page...
 
/lp/oxford-university-press/retraction-of-effects-of-valsartan-on-morbidity-and-mortality-in-Ip2Glla68o

References (2)

Publisher
Oxford University Press
Copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2013. For permissions please email: journals.permissions@oup.com
Subject
RETRACTION
ISSN
0195-668X
eISSN
1522-9645
DOI
10.1093/eurheartj/eht030
pmid
23376450
Publisher site
See Article on Publisher Site

Abstract

The Editor’s Page 1023 11. Fanelli D. How many scientists fabricate and falsify research? A systematic review surgery: a randomized controlled trial (DECREASE-IV). Ann Surg 2009;249: and meta-analysis of survey data. PLoS One 2009;4:e5738. 921–926. 12. Nallamothu B, Lu¨scher TF. Moving from impact to influence: measurement and 30. Poldermans D, Schouten O, Benner R, van Urk H, Verhagen HJ, Khan N, the changing role of medical journals. Eur Heart J 2012;33:2892–2996. Feringa H, Dunkelgrun M, Bax JJ, Boersma E. Fluvastatin XL use is associatedwith 13. Marcus A, Oransky I. A retraction epidemic. New York Times 2012;April, p7. improved cardiac outcome after major vascular surgery. Results from a rando- 14. Steen RG. Retractions in the scientific literature: is the incidence of research fraud mized placebo controlled trial: DECREASE III. Circulation 2008;118:S792. increasing? J Med Ethics 2011;37:249–253. 31. Poldermans D, Bax JJ, Schouten O, Neskovic AN, Paelinck B, Rocci G, van 15. Fang FC, Casadevall A. Retracted science and the retraction index. Infect Immun Dortmont L, Durazzo AE, van de Ven LL, van Sambeek MR, Kertai MD, 2011;79:3855–3859. Boersma E. Should major vascular surgery be delayed because of preoperative 16. Notice of Concern. J Am Coll Cardiol 2012;60:2696–2697. cardiac testing in intermediate-risk patients receiving beta-blocker therapy with 17. Wise J. Extent of Durch psychologist’s trial fraud was unprecendented. BMJ 2011; tight heart rate control? J Am Coll Cardiol 2006;48:964–969. 343:969. 32. Poldermans D, Bax JJ. Dobutamine echocardiography: a diagnostic tool comes of 18. O’Riordan M. Erasmus MC fires Poldermans; ESC reviews his work. www. age. Eur Heart J 2003;24;1541–1542. theheart.org/article/1315171.do (27 February 2013). 33. Hoeks SE, Bax JJ, Poldermans D. Should the ACC/AHA guidelines be changed in 19. Expression of concern. Circ Res 2012;110:e47. patients undergoing vascular surgery? Eur Heart J 2005;26:2358–2360. 20. Yoshiki Y. Concerns about the Jikei Heart Study. Lancet 2012;379:e48. 34. Poldermans D, Bax . Selecting optimal non-invasive cardiac imaging stress test in 21. Shimokawa H. Urgent announcement from the editor-in-chief concerning atricle intermediate-risk patients using cost effectiveness analysis. Eur Heart J 2006;27: retraction. Circ J 2013;77:552b. 2378–2379. 22. Lu¨scher TF. In search of the right word: a statement of the HEART Group on 35. Hoeks SE, Bax JJ, Poldermans D. Indications of prophylactic coronary revascular- scientific language. Eur Heart J 2013;34:7–9. ization in patients undergoing major vascular surgery; the saga continues. Eur 23. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. Heart J 2007;28:519–521. p104–108. 36. Schouten O, Bax JJ, Poldermans D. Preoperative cardiac risk assessment in vascu- 24. Stewart WW, Feder N. The integrity of the scientific literature. Nature 1987;325: lar surgery patients; seeing beyond the perioperative period. Eur Heart J 2008;29: 207–214. 283–284. 25. Braunwald E. On analysing scientific fraud. Nature 1987;325:215–216. 37. Flu WJ, Van Kuijk JP, Gorscan J, Poldermans D. Three-dimensional speckle track- 26. Judson HF. The Great Betrayal. Fraud in Science. Orlando, FL: Harcourt Inc.; 2004. ing echocardiography: a novel approach in the assessment of left ventricular p110–112. volume and function? Eur Heart J 2009;30:2304–2307. 27. Broad WJ. Imbroglio at Yale: emergence of a fraud. Science 1980;210:38–41 and 38. Van Kuijk JP, Flu WJ, Welten GM, Hoeks SE, Chronchol M, Vidakowic R, 10:171–173. Verhagen HJ, Bax JJ, Poldermans D. Long-term prognosis of patients with periph- 28. Feringa HH, Elhendy A, Bax JJ, Boersma E, de Jonge R, Schouten O, eral arterial disease with or without polyvascular atherosclerotic disease. Eur Karagiannis SE, Schinkel AF, Lindemans J, Poldermans D. Baseline plasma Heart J 2010;31:992–999. N-terminal pro-B-type natriuretic peptide is associated with the extent of 39. Wednesday 28 November 2012. stress-induced myocardial ischemia during dobutamine stress echocardiography. 40. Lu¨scher TF, Gersh B, Brugada J, Landmesser U, Ruschitzka F, Serruys PW on Coron Artery Dis 2006:17; 255–259 and Feringa HH, Bax JJ, Elhendy A, de Jonge behalf of the new editorial board. The European Heart Journal goes global: the R, Lindemans J, Schouten O, van den Meiracker AH, Boersma E, Schinkel AF, road ahead of the editorial team 2009–2011. Eur Heart J 2009;30:1–5. Kertai MD, van Sambeek MR, Poldermans D. Association of plasma N-terminal 41. Head SJ, Kaul S, Bogers AJJC, Kappetein AP. Non-inferiority study design: lessons pro-B-type natriuretic peptide with postoperative cardiac events in patients to be learned from cardiovascular trials. Eur Heart J 2012;33;1318–1324. undergoing surgery for abdominal aortic aneurysm or leg bypass. Am J Cardiol 42. Heinze G, Ju¨ni P. An overview of the objectives of the approaches to propensity 2006;98:111–115. analysis. Eur Heart J 2011;32;1704–1708. 29. Dunkelgrun M, Boersma E, Schouten O, Koopman-van Gemert AW, van 43. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Poorten F, Bax JJ, Thomson IR, Poldermans D; Dutch Echocardiographic Trikalinos TA, Kitsios GD. Do observational studies using propensity score Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisopro- methods agree with randomized trials? A systematic comparison of studies on lol and fluvastatin for the reduction of perioperative cardiac mortality and myo- acute coronary syndromes. Eur Heart J 2012;33:1893–1901. cardial infarction in intermediate-risk patients undergoing noncardiovascular 44. Norman C. Reduce fraud in seven easy steps. Science 1984;224;581. doi:10.1093/eurheartj/eht030 Retraction Online publish-ahead-of-print 1 February 2013 ............................................................................................................................................................................. Retraction of: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study [Eur Heart J (2009) 30:2461–2469, doi: 10.1093/eurheartj/ehp363]. 1 1 2 1 1 Takahisa Sawada , Hiroyuki Yamada , Bjo¨rn Dahlo¨f , and Hiroaki Matsubara for the KYOTO HEART Study Group 1 2 Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kajiicho 465, Kamigyoku, Kyoto 602-8566, Japan and Department of Medicine, Sahlgrenska University Hospital/Ostra, Go¨teborg, Sweden This article has been retracted by the journal. Critical problems existed with some of the data reported in the above paper. The editors of the European Heart Journal hereby retract this paper and discourage citations of it. Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2013. For permissions please email: journals.permissions@oup.com

Journal

European Heart JournalOxford University Press

Published: Apr 7, 2013

There are no references for this article.